COST-UTILITY ANALYSIS OF SOFOSBUVIR FOR TREATMENT OF GENOTYPE2 CHRONIC HEPATITIS C IN JAPAN

被引：1
|
作者：
Igarashi, A. [1 ]
Tang, W. [1 ]
Cure, S. [2 ]
Guerra, I [2 ]
Lopresti, M. [3 ]
Tsutani, K. [1 ]
机构：
[1] Univ Tokyo, Grad Sch Pharmaceut Sci, Tokyo, Japan
[2] OptumInsight, Uxbridge, Middx, England
[3] Junicon Japan Inc, Minato Ku, Tokyo, Japan
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.827
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI30
引用
收藏
页码：A368 / A368
页数：1
相关论文
共 50 条
  • [31] Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence
    Gimeno-Ballester, Vicente
    Angel Simon, Miguel
    Trigo, Cristina
    Mar, Javier
    San Miguel, Ramon
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 10 (11) : 1289 - 1303
  • [32] Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection
    Sundaram, Vinay
    Kowdley, Kris V.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 10 (01) : 13 - 20
  • [33] Cost-utility analysis for smoking cessation therapy in Japan
    Igarashi, A.
    Fukuda, T.
    Oshima, A.
    Nakamura, M.
    Tsutani, K.
    VALUE IN HEALTH, 2006, 9 (06) : A384 - A384
  • [34] COST-UTILITY ANALYSIS OF ROTAVIRUS VACCINE (ROTARIX®) IN JAPAN
    Igarashi, A.
    Fukuda, T.
    Orihara, S.
    Suzuki, H.
    Tsutani, K.
    VALUE IN HEALTH, 2009, 12 (07) : A429 - A429
  • [35] Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: A cost-utility analysis
    Arguedas, MR
    Chen, VK
    Eloubeidi, MA
    Fallon, MB
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (03): : 679 - 690
  • [36] Comparison of Sofosbuvir Plus Ribavirin Treatment with Pegylated Interferon Plus Ribavirin Treatment for Chronic Hepatitis C Genotype 2
    Seo, Kayo
    Kim, Soo Ki
    Kim, Soo Ryang
    Ohtani, Aya
    Kobayashi, Mana
    Kato, Airi
    Morimoto, Eri
    Saijo, Yuka
    Kim, Ke Ih
    Imoto, Susumu
    Kim, Chi Wan
    Yano, Yoshihiko
    Kudo, Masatoshi
    Hayashi, Yoshitake
    DIGESTIVE DISEASES, 2017, 35 (06) : 541 - 547
  • [37] Sofosbuvir and velpatasvir in the treatment of chronic hepatitis C
    Wuerth, Kelli
    Magel, Tianna
    Conway, Brian
    FUTURE VIROLOGY, 2019, 14 (11) : 715 - 727
  • [38] Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
    Jacobson, Ira M.
    Gordon, Stuart C.
    Kowdley, Kris V.
    Yoshida, Eric M.
    Rodriguez-Torres, Maribel
    Sulkowski, Mark S.
    Shiffman, Mitchell L.
    Lawitz, Eric
    Everson, Gregory
    Bennett, Michael
    Schiff, Eugene
    Al-Assi, M. Tarek
    Subramanian, G. Mani
    An, Di
    Lin, Ming
    McNally, John
    Brainard, Diana
    Symonds, William T.
    McHutchison, John G.
    Patel, Keyur
    Feld, Jordan
    Pianko, Stephen
    Nelson, David R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (20): : 1867 - 1877
  • [39] Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis
    Ferreira, Vinicius L.
    Assis Jarek, Nayara A.
    Tonin, Fernanda S.
    Borba, Helena H. L.
    Wiens, Astrid
    Muzzillo, Dominique A.
    Pontarolo, Roberto
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 (04) : 749 - 755
  • [40] COST-UTILITY ANALYSIS OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALPHA AND RIBAVIRIN IN PREVIOUSLY TREATED PATIENTS WITH CHRONIC HEPATITIS C
    Lukac, M.
    Bielik, J.
    Holoman, J.
    Tomek, D.
    Suvadova, A.
    Foltanova, T.
    Foltan, V
    VALUE IN HEALTH, 2012, 15 (07) : A330 - A330
12345